Larry Rubinstein

National Institutes of Health — United States

Medicine · Health Sciences

70h-index66.0kcitations462works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(80), Cancer Genomics and Diagnostics(65), Statistical Methods in Clinical Trials(61), PARP inhibition in cancer therapy(59), Colorectal Cancer Treatments and Studies(52)

Publications461 total

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors
Cancer Chemotherapy and Pharmacology·2025Open Access
Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025Open Access
Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i>, <i>2</i>, or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
2025Open Access
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i> -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
JCO Precision Oncology·2025
1709MO Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Annals of Oncology·2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
JCO Precision Oncology·2025· 1 cited
Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer
JAMA Oncology·2025· 3 citedOpen Access
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors
JCO Precision Oncology·2025Open Access
Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
Clinical Cancer Research·2025· 3 citedOpen Access
Supplementary Figure S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Figure S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
2025Open Access
page 1 of 24Next →

Frequent Co-authors

Alice P. Chen(10), James H. Doroshow(7), Keith T. Flaherty(7), Robert J. Gray(7), Lisa M. McShane(7), David R. Patton(7), Stanley R. Hamilton(7), P. Mickey Williams(7), Edith P. Mitchell(7), Lyndsay N. Harris(7), James A. Zwiebel(7), Carlos L. Arteaga(7), Barbara A. Conley(7), Daniel J. Sargent(6), Robert J. Kinders(6), Shuli Li(6), Peter J. O’Dwyer(6), Lawrence H. Schwartz(5), Janet Dancey(5), Susan G. Arbuck(5)